Lattice Biologics Ltd. (LBLTF)
| Market Cap | 128.00 |
| Revenue (ttm) | 1.56M |
| Net Income (ttm) | -951.65K |
| Shares Out | 128.22M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Average Volume | 14,903 |
| Open | 0.0000 |
| Previous Close | 0.0000 |
| Day's Range | 0.0000 - 0.0000 |
| 52-Week Range | 0.0000 - 0.0000 |
| Beta | 1.15 |
| RSI | 41.21 |
| Earnings Date | n/a |
About Lattice Biologics
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; and acellular dermal matrix that provides a natural collagen tissue scaffold that promotes cellular ingrowth, tissue vascularization,... [Read more]
Financial Performance
In fiscal year 2020, Lattice Biologics's revenue was $2.46 million, an increase of 12.60% compared to the previous year's $2.19 million. Losses were -$1.48 million, 46.5% more than in 2019.
News
Lattice Biologics Ltd. Reports Second Quarter 2021 Results and Resumes Trading
ISLAND PARK, Id.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q2 2021. Highlights of Six Months Ended Mar...
Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies
BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announced today that the Company will change its business strategy to focus ...
Lattice Biologics Ltd. Announces Resignation of Director
BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces that Mr. Donald McInnes has resigned as a director of the Company,...
Lattice Biologics Ltd. Reports First Quarter 2021 Highlights
BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q1 2021. Highlights of Three Months Ended De...